Life Sciences

Embedded in the Life Sciences Ecosystem

With over 200+ industry-focused practitioners worldwide, our team represents life sciences companies across the industry spectrum: therapeutics, vaccines, medical devices, research tools, diagnostics, as well as investment banks, venture capital firms, and other investors. Our work for these clients encompasses intellectual property, corporate, regulatory, litigation, employment, real estate, and other matters. We are embedded in the global life sciences ecosystem and provide industry leaders with practical solutions to business-critical challenges, helping them navigate the complex regulatory and global business environment in which they operate to successfully achieve their goals.

Awards

Chambers USA

Recognized for Litigation, Health Law, M&A, and Capital Markets

LMG Life Sciences

3 Highly Ranked Practices

Legal 500 United States

Recommended for Life Sciences

Managing Intellectual Property

Top Life Science Patent Practice

Best Law Firms 2025

Nationally ranked Tier 1 for Health Care

Patexia

Ranked as the Top 10 Most Active Law Firm for Biotech Patents (Patexia, 2024).

Our Experience

Mintz Advises on ArriVent BioPharma’s Upsized IPO on the Nasdaq Global Market

Mintz advised client ArriVent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, on its upsized $175 million IPO on Nasdaq.

$50B+ in transactions handled since 2020

including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings

Representing Synlogic, Inc. from Inception to IPO

Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.

Our Approach

There is no one-size-fits-all approach for life sciences clients. But, our integrated intellectual property, regulatory, litigation, and corporate practices provide a one-size-fits-all TEAM for all clients. We help entrepreneurs launch great ideas from the lab. We help growing companies get funded and navigate the complex web of regulatory approvals. We help public companies remain compliant with SEC requirements. We help investors and underwriters secure positions as industry leaders. We help companies strategically expand and protect their IP assets – including the new terrain of artificial intelligence and machine learning. And, we assist clients in mitigating risk and navigating high-stakes commercial, regulatory, and IP litigation. Life sciences companies rely on Mintz to address all of their legal needs at all stages of their life cycle.

Corporate – $43B+ in transactions handled since 2020 for industry clients, including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings.
Intellectual Property – more than 130 professionals who represent clients in prosecution, strategy, business transactions, and litigation – 40+ of whom have biology or chemistry PhDs.
Litigation – national reputation as go-to firm for high-stakes life sciences litigation, with an exemplary record in resolving disputes with collaboration/licensing partners in court and in arbitration, and representing corporate officers and directors of life sciences companies in disputes.
Regulatory – advice spanning FDA strategy and interactions, clinical trials, fraud and abuse, compliance program development, HIPAA, marketing and advertising, drug pricing and reimbursement, and supply and distribution agreements.
Cross-Border Capabilities – we have built the most integrated cross-border team among North American law firms to provide seamless service on matters involving industry-focused US and Canadian businesses and investors.

Areas of focus:

Corporate

Initial public offerings & follow-on public offerings
Reverse mergers / SPACs
Private placements
Royalty & Revenue Interest Financing
Corporate governance
Mergers and acquisitions
Strategic collaborations and licensing
Venture capital and emerging companies
MintzEdge (www.mintzedge.com)

Intellectual Property

Patent prosecution and strategy
Patent infringement litigation – District Court, ITC
Post-grant proceedings – IPRs, PGRs
Trademark strategy and registration
Trade secrets
Artificial Intelligence (AI) and machine learning
Arbitration, mediation, and other alternative dispute resolution

Litigation

Partnership and JV disputes
Arbitration and mediation
Securities
Government investigations and enforcement
Products liability
Patent infringement
Trade secrets
Contracts

Regulatory

FDA regulatory strategy and interactions
Clinical trials and research
Compliance, fraud and abuse, and regulatory counseling
Drug pricing and reimbursement
HIPAA privacy and security
Marketing and advertising

What Our Clients Are Saying

Experienced guide for negotiating the regulatory environments overseen by the SEC and FDA. Highlighted for its skilled representation of emerging companies in public and private securities offerings, M&A transactions and strategic partnerships. Noted for its depth of experience assisting with matters related to reverse mergers.